Department of Internal Medicine, Division of Metabolism and Endocrinology, St Marianna University School of Medicine, Kanagawa, Japan.
Matsuba Medical Clinic, Kanagawa, Japan.
Diabetes Obes Metab. 2018 May;20(5):1311-1315. doi: 10.1111/dom.13211. Epub 2018 Feb 4.
The impact of tofogliflozin, a sodium-glucose co-transporter-2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic-euglycaemic clamp method in a single-arm, open-label study. The following variables were compared between before and after tofogliflozin administration for 12 weeks in 16 patients with T2DM who were receiving dipeptidyl peptidase-4 inhibitor treatment: body weight (BW); blood pressure; glucose metabolism; liver function; lipid profile; and body composition. Peripheral glucose uptake (M value and M/I ratio) was examined by the hyperinsulinaemic-euglycaemic clamp method. After 12 weeks, there was a significant decrease (P < .001) in glycated haemoglobin, BW, body fat mass and lean body mass. Peripheral glucose uptake, which indicates insulin sensitivity, increased significantly (M value by 0.90 and M/I ratio by 0.49; both P < .05). The change in the M value after 12 weeks of tofogliflozin therapy was correlated with the change in body fat mass (P < .05). Tofogliflozin significantly improved insulin sensitivity and peripheral glucose uptake in patients with T2DM. These improvements were significantly correlated with reduction in body fat mass.
使用高胰岛素-正葡萄糖钳夹法，在一项单臂、开放标签研究中，评估钠-葡萄糖共转运蛋白 2 抑制剂托格列净对 2 型糖尿病（T2DM）患者外周葡萄糖摄取的影响。在接受二肽基肽酶-4 抑制剂治疗的 16 例 T2DM 患者中，比较了托格列净治疗 12 周前后的以下变量：体重（BW）；血压；葡萄糖代谢；肝功能；血脂谱；和身体成分。通过高胰岛素-正葡萄糖钳夹法检查外周葡萄糖摄取（M 值和 M/I 比值）。12 周后，糖化血红蛋白、BW、体脂肪量和去脂体重显著下降（P <.001）。外周葡萄糖摄取（胰岛素敏感性的指标）显著增加（M 值增加 0.90，M/I 比值增加 0.49；均 P <.05）。托格列净治疗 12 周后 M 值的变化与体脂肪量的变化相关（P <.05）。托格列净显著改善了 T2DM 患者的胰岛素敏感性和外周葡萄糖摄取。这些改善与体脂肪量的减少显著相关。
